References
- 1. Kwan P. Schachter SC, Brodie MJ. Drug-resistant epilepsy. N. Engl J Med. 2011 Sept;365(10):912-6. DOI: 10.1056/NEJMra1004418
- 2. Löscher W. How to explain multidrug resistance in epilepsy? Epilepsy Curr. 2005 May-Jun;5(3):107-12. DOI: 10.1111/j.1535-7511.2005.05311.x
- 3. Buzoianu AD, Sabin O, Bocşan CI, Militaru C. MDR gene polymorphism and refractory epilepsy. Therapeutics, Pharmacology and Clinical Toxicology. 2009;13(4):375-80.
- 4. Sánchez MB, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizán EM, Nicolás JM, et al. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure. 2010 Mar;19(2):93-101. DOI: 10.1016/j.seizure.2009.12.004
- 5. Thishler DM, Weinberg KI, Hinton DR, Barbaro N, Annet GM, Raffael C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia. 1995 Jan;36(1):1-6. DOI: 10.1111/j.1528-1157.1995. tb01657.x
- 6. Dombrovski SM, Desai SJ, Marroni M, Cucullo L, Goodrich K, Bingaman W, et al. Overexpression of multidrug resistance genes in endothelial cell from patients with refractory epilepsy. Epilepsia. 2001 Dec;42(12):1501-6. DOI: 10.1046/j.1528-1157.2001.12301.x
- 7. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med. 2003 Apr;348(15):1442–8. DOI: 10.1056/NEJMoa021986
- 8. Kim DW, Kim M, Lee SK, Kang R, Lee SY. Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy. Seizure. 2006 Jul;15(5):344–7. DOI: 10.1016/j.seizure.2006.02.015
- 9. Lakhan R, Misra UK, Kalita J, Pradhan S, Gogtay NJ, Singh MK, et al. No association of ABCB1 polymorphisms with drug-refractory epilepsy in a north Indian population. Epilepsy Behav. 2009 Jan;14(1):78–82. DOI: 10.1016/j.yebeh.2008.08.019
- 10. Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y. Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis. Epilepsia. 2009 Apr;50(4):898–903. DOI: 10.1111/j.1528-1167.2008.01858.x
- 11. Saygi S, Alehan F, Atac FB, Erol I, Verdi H, Erdem R. Multidrug resistance 1 (MDR1) 3435C/T genotyping in childhood drug-resistant epilepsy. Brain Dev. 2014 Feb;36(2):137-42. DOI: 10.1016/j.braindev.2013.01.016
- 12. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99. DOI: 10.1111/j.1528-1157.1989.tb05316.x
- 13. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010 Jun;51(6):1069–77. DOI: 10.1111/j.1528-1167.2009.02397.x
- 14. Hao X, Goldberg D, Kelly K, Stephen L, Kwan P, Brodie MJ. Uncontrolled epilepsy is not necessarily the same as drug-resistant epilepsy: differences between populations with newly diagnosed epilepsy and chronic epilepsy. Epilepsy Behav. 2013 Oct;29(1):4–6. DOI: 10.1016/j.yebeh.2013.06.019
- 15. Dong L, Luo R, Tong Y, Cai X, Mao M, Yu D. Lack of association between ABCB1 gene polymorphism and pharmacoresistant epilepsy: An analysis in a western Chinese pediatric population. Brain Res. 2011 May;91(13):114-24. DOI: 10.1016/j.brainres.2011.03.028
- 16. Marusteri M, Bacarea V. Kako odabrati pravi test za procjenu statističke značajnosti razlike između skupina?/Comparing groups for statistical differences: how to choose the right statistical test? Biochem Med. 2010;20(1):15-32. DOI: 10.11613/BM.2010.004
- 17. Shorvon SD. The etiological classification of epilepsy. In Shorvon SD, Andermann F, Guerrini R (Eds). The causes of epilepsy. Common and uncommon causes in adults and children. Cambridge University Press, Cambridge, 2011b; 21–23. DOI: 10.1017/CBO9780511921001 DOI: 10.1017/CBO9780511921001.004
- 18. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross HJ, van Emde BW, Engel J Jr, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;51(4):676-85. DOI: 10.1111/j.1528-1167.2010.02522.x
- 19. Juárez IM, Vanegas LE, Rodríguez NR, Aldana JAL, Escueta AVD. Gene involved in Pharmacoresistant epilepsy, in Rocha L, Cavalheiro EA (eds.), Pharmacoresistance in Epilepsy: From Genes and Molecules to Promising Therapies. Springer Science-Business Media, LLC. 2013:11-25 ISBN: 978-1-4614-6463-1 DOI: 10.1007/978-1-4614-6464-8_2
- 20. Berg AT. Epilepsies. In Panayiotopoulos CP (Ed). Atlas of epilepsies. Vol 2. Springer. London 2010:732-756 DOI: 10.1007/978-1-84882-128-6_2
- 21. Sisodiya SM, Lint WR, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: human epilepsy. Novartis Found Symp. 2002;243:167-74; discussion 174-9, 180-5.
- 22. Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009;50:1–23. DOI: 10.1016/S0920-1211(02)00062-1 DOI: 10.1111/j.1528-1167.2008.01716.x
- 23. Brandt C, Bethmann K, Gastens AM, Löscher W. The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis. 2006 Oct;24(1):202-1. DOI: 10.1016/j.nbd.2006.06.014
- 24. Das A, Balan S, Banerjee M, Radhakrishnan K. Drug resistance in epilepsy and the ABCB1 gene: The clinical perspective. Indian J Hum Genet.2011 May;17(4):12-21. DOI: 10.4103/0971-6866.80353
- 25. Seo T, Ishitsu T, Ueda N, Nakada N, Yurube K, Ueda K, et al. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics. 2006 Jun;7(4):551-61. DOI: 10.2217/14622416.7.4.551
- 26. Sporis D, Basic S, Bozina N, Babic T, Hajnsek S, Sertic J, et al. ABCB1 gene variants as predictors of drug resistant epilepsy in Croatian population. Neurol. Croat.2011;60(2):63-9.
- 27. Zimprich F, Sunder-Plassmann R, Stogmann E, Gleiss A, Dal Bianco A, Zimprich A, et al. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology. 2004 Sep;63(6):1087-9. DOI: 10.1212/01.WNL.0000141021.42763.F6
- 28. Seven M, Batar B, Unal S, Yesil G, Yuksel A, Guven M. The drug-transporter gene MDR1 C3435T and G2677T/A polymorphisms and the risk of multidrug resistant epilepsy in Turkish children. Mol Biol Rep. 2014 Jan;41(1):331–6. DOI: 10.1007/s11033-013-2866-y
- 29. Haerian BS, Lim KS, Tan HJ, Mohamed E, Tan CT, Raymond AA, et al. Association between ABCB1 polymorphism and response to sodium valproate treatment in Malaysian epilepsy patients. Epileptic Disord. 2011 Mar;13(1):65-75.
- 30. Vahab SA, Sen S, Ravindran N, Mony S, Mathew A, Vijayan N, et al. Drug Metab Pharmacokinet. 2009;24(3):255-60. DOI: 10.2133/dmpk.24.255
- 31. Tuychibaeva NM, Karimov K.Ya, Alimakhodjaeva PR, Prokhorova AV, Shamsutdinova DB, Boboev KT. MDR1 gene C3435T and C1236T polymorphism among patients with pharmacoresistant epilepsy and healthy individuals. International Journal of BioMedicine. 2014 Dec;4(4):209-12.
- 32. Naumovska Z, Nestorovska AK, Sterjev Z, Filipce A, Dimovski A, Suturkova L. Genotype variability and haplotype profile of ABCB1 (MDR1) gene polymorphism in Macedonian population. Prilozi.2014;35(3):121-33.
- 33. Milojkovic M, Stojnev S, Jovanovic I, Ljubisavljevic S, Stefanovic V, Sunder-Plassman R. Frequency of the C1236T, G2677T/A and C3435T MDR1 gene polymorphisms in the Serbian population. Pharmacol Rep. 2011;63(3):808–14. DOI: 10.1016/S1734-1140(11)70593-X
- 34. Sipeky C, Csongei V, Jaromi L, Safrany E, Maasz A, Takacs I, Beres J, et al. Genetic variability and haplotype profile of MDR1 (ABCB1) in Roma and Hungarian population samples with a review of the literature. Drug Metab Pharmacokinet.2011;26(2):206–15. DOI: 10.2133/dmpk.DMPK-10-SC-068
- 35. Petrova DT, Nedeva P, Maslyankov S, Toshev S, Yaramov N, Atanasova S, et al. No association between MDR1 (ABCB1) 2677G > T and 3435C > T polymorphism and sporadic colorectal cancer among Bulgarian patients. Cancer Res Clin Oncol. 2008 Mar;134(3):317–22. DOI: 10.1007/s00432-007-0279-9
- 36. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, Köpke K, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol. 2003 Aug; 59(4):303–12. DOI: 10.1007/s00228-003-0606-2
- 37. Lee SS, Kim SY, Kim WY, Thi-Le H, Yoon YR, Yea SS, et al. MDR1 genetic polymorphisms and comparison of MDR1 haplotype profiles in Korean and Vietnamese populations. Ther Drug Monit. 2005 Aug;27(4):531–5. DOI: 10.1097/01.ftd.0000164293.75854.11
- 38. Estrela RC, Ribeiro FS, Carvalho RS, Gregório SP, Dias-Neto E, Struchiner CJ, et al. Distribution of ABCB1 polymorphisms among Brazilians: impact of population admixture. Pharmacogenomics. 2008 Mar;9(3):267–76. DOI: 10.2217/14622416.9.3.267
- 39. Buzoianu A, Bocsan IC, Maier C, Trifa AP, Poop RA, Perju Dumbrava L, et al. Genotype-phenotype correlation between the alleles of the MDR1 C3435T polymorphism and pharmackochinetic parameters in Romanian epileptic patients. Therapeutics Pharmacology and Clinical Toxicology. 2011 Mar;15(1):40-4.